For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CES865. CME credit will be available until October 9, 2025.
Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
View all episodes
By PVI, PeerView Institute for Medical Education
4
1010 ratings
For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/CES865. CME credit will be available until October 9, 2025.
Updating the Lung Cancer Treatment Algorithms With Novel Antibody–Drug Conjugates: Are You Prepared for Change? State of the Science, Implications for Practice, and Future Prospects
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Daiichi Sankyo, Inc.
Disclosure information is available at the beginning of the video presentation.
135 Listeners
320 Listeners
496 Listeners
40 Listeners
27 Listeners
10 Listeners
5 Listeners
10 Listeners
4 Listeners
2 Listeners
5 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
115 Listeners
2 Listeners
4 Listeners
57 Listeners
3 Listeners
5 Listeners
3,332 Listeners
44 Listeners
22 Listeners
2 Listeners
365 Listeners
54 Listeners
58 Listeners
189 Listeners